306 related articles for article (PubMed ID: 24030946)
1. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
[TBL] [Abstract][Full Text] [Related]
5. Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes.
Kim G; Jo K; Kim KJ; Lee YH; Han E; Yoon HJ; Wang HJ; Kang ES; Yun M
Cardiovasc Diabetol; 2015 Nov; 14():148. PubMed ID: 26538247
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT.
Tahara N; Yamagishi S; Kodama N; Tahara A; Honda A; Nitta Y; Igata S; Matsui T; Takeuchi M; Kaida H; Kurata S; Abe T; Fukumoto Y
J Clin Endocrinol Metab; 2015 May; 100(5):E739-47. PubMed ID: 25695885
[TBL] [Abstract][Full Text] [Related]
7. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.
Kim TN; Kim S; Yang SJ; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Circ Cardiovasc Imaging; 2010 Mar; 3(2):142-8. PubMed ID: 20061516
[TBL] [Abstract][Full Text] [Related]
8. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
Tahara N; Yamagishi S; Mizoguchi M; Tahara A; Imaizumi T
Rejuvenation Res; 2013 Oct; 16(5):344-51. PubMed ID: 23777507
[TBL] [Abstract][Full Text] [Related]
10. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
11. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
Elkhawad M; Rudd JH; Sarov-Blat L; Cai G; Wells R; Davies LC; Collier DJ; Marber MS; Choudhury RP; Fayad ZA; Tawakol A; Gleeson FV; Lepore JJ; Davis B; Willette RN; Wilkinson IB; Sprecher DL; Cheriyan J
JACC Cardiovasc Imaging; 2012 Sep; 5(9):911-22. PubMed ID: 22974804
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Activity in the Visceral and Subcutaneous Adipose Tissues by FDG-PET/CT in Obese Patients.
Monteiro AM; Ferreira G; Duarte H
Acta Med Port; 2017 Nov; 30(11):813-817. PubMed ID: 29279074
[TBL] [Abstract][Full Text] [Related]
13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
15. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
18. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Punthakee Z; Alméras N; Després JP; Dagenais GR; Anand SS; Hunt DL; Sharma AM; Jung H; Yusuf S; Gerstein HC
Diabet Med; 2014 Sep; 31(9):1086-92. PubMed ID: 24890138
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Nakayama T; Komiyama N; Yokoyama M; Namikawa S; Kuroda N; Kobayashi Y; Komuro I
Int J Cardiol; 2010 Jan; 138(2):157-65. PubMed ID: 18817993
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
